10-K: Rocket Pharmaceuticals Reports 2024 Financial Results, Provides Business Update

Sentiment:

Annual Results 27 February 2025 4:01 PM

📋All filings for Rocket Pharmaceuticals, INC

Rocket Pharmaceuticals details its financial performance for 2024 and outlines key advancements in its gene therapy programs.

Delay expectedThe FDA issued a Complete Response Letter for RP-L201, delaying potential approval.

Capital raiseThe company completed a public offering and private placement in December 2024, raising net proceeds of $182.5 million.The company may consider reactivating the at-the-market offering program in the future.

Worse than expectedThe company reported a net loss of $258.7 million for 2024, which is worse than the $245.6 million net loss reported in 2023.

Summary

Rocket Pharmaceuticals, a late-stage biotechnology company, reported a net loss of $258.7 million for the year ended December 31, 2024.
The company is focused on developing gene therapies for rare and devastating diseases.
Key programs include RP-A501 for Danon disease (DD), RP-A601 for Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), and RP-L201 for Leukocyte Adhesion Deficiency-I (LAD-I).
Enrollment in the Phase 2 pivotal trial for RP-A501 in DD was completed in September 2024.
The FDA issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) for RP-L201, requesting additional CMC information.
Submission of a complete BLA to resolve the CRL is anticipated in 2025.
The company initiated a Phase 1 study for RP-A601.
An Investigational New Drug (IND) application for BAG3 Dilated Cardiomyopathy (BAG3-DCM) is anticipated in the first half of 2025.
Research and development expenses totaled $171.2 million for 2024.
General and administrative expenses were $102.0 million for 2024.
As of December 31, 2024, Rocket Pharmaceuticals had $372.3 million in cash, cash equivalents, and investments.
The company expects these resources to fund operations into the third quarter of 2026.
The company completed a public offering and private placement in December 2024, raising net proceeds of $182.5 million.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive developments in clinical trials and successful fundraising, the significant net loss and regulatory hurdles temper the overall outlook.

Positives

Enrollment is complete in the Phase 2 study of RP-A501 for Danon Disease.
The company initiated a Phase 1 study for RP-A601.
The company expects its current resources to fund operations into the third quarter of 2026.
A public offering and private placement in December 2024 generated $182.5 million in net proceeds.
EMA accepted the MAA for RP-L102 on April 2, 2024.

Negatives

Rocket Pharmaceuticals reported a net loss of $258.7 million for 2024.
The FDA issued a Complete Response Letter for RP-L201, requiring additional CMC information.
The at-the-market offering program is not currently available to the company.

Risks

The company has a history of operating losses and may not achieve or sustain profitability.
Clinical trials may encounter delays or fail to demonstrate safety and efficacy.
The company may need to raise additional funding, which may not be available on acceptable terms.
The company faces intense competition and rapid technological change.
The company relies on third parties for manufacturing and clinical trials.
The company is subject to stringent laws and regulations regarding data privacy and security.

Future Outlook

The company expects its current resources to fund operating expenses and capital expenditure requirements into the third quarter of 2026. IND submission for BAG3-DCM is anticipated in the first half of 2025. Submission of complete BLA to resolve Complete Response Letter anticipated in 2025.

Management Comments

We seek to bring hope and relief to patients with devastating, undertreated and rare pediatric diseases through the development and commercialization of potentially curative first in class gene therapies.
As a fully-integrated biotechnology company, we are well positioned to achieve these objectives.
In the near and medium-term, we intend to develop our first-in-class product candidates, which target devastating diseases with substantial unmet need, develop proprietary in-house analytics and manufacturing capabilities and continue to conduct registration trials for our currently planned programs.
In the medium and long-term, pending favorable data, we expect to submit BLAs for the rest of our suite of clinical programs, and establish our gene therapy platform and expand our pipeline to target additional indications that we believe to be potentially compatible with our gene therapy technologies.

Industry Context

The biotechnology and pharmaceutical industries, including in the field of gene therapy, are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products and novel therapies.

Comparison to Industry Standards

The FDA approval of several gene therapies in recent years indicates that there is a regulatory pathway forward for gene therapy products.
Competitors include larger and better-funded pharmaceutical and biotechnology companies, new market entrants and new technologies, as well as from academic institutions, government agencies and private and public research institutions, which may in the future develop products to treat the indications targeted by our pipeline that have not yet been conceived.
Any product candidates that we successfully develop and commercialize will compete with existing therapies such as bone marrow transplantation and new therapies that may become available in the future.

Legal Proceedings

On October 12, 2023, the Company filed an action in the U.S. District Court for the Southern District of New York against Lexeo Therapeutics, Inc., Kenneth Law, and Sonia Gutierrez, Case No. 23-cv-9000 (PKC).
On December 31, 2024, the Company filed an action in the U.S. District Court for the District of Oregon against Brian C. Beard and Little Whiskers, LLC, Case No. 3:24-cv-02170-SI.

Related Party Transactions

In June 2023, the Company entered into a consulting agreement with the spouse of one of the Companys executive officers for information technology advisory services.
On September 15, 2023, in connection with the Companys public offering, the Company sold approximately 3.1 million pre-funded warrants to purchase shares of the Companys common stock to funds affiliated with RTW, the Companys largest shareholder.
On December 12, 2024, in connection with the Companys public offering, the Company sold 0.4 million pre-funded warrants to purchase shares of the Companys common stock to funds affiliated with RTW, the Companys largest shareholder.
In February 2025, the Company enter into a consulting agreement with one of the Companys board members, effective March 3, 2025 , for services related to the Companys research and development activities.

Stakeholder Impact

The company's progress in gene therapy development has the potential to significantly impact patients with rare and devastating diseases.
The company's financial performance and strategic decisions affect shareholders.
The company's operations and expansion plans impact employees and potential employees.

Next Steps

Submission of complete BLA to resolve Complete Response Letter anticipated in 2025.
IND submission for BAG3-DCM is anticipated in the first half of 2025.
Continue dosing and follow-up in the Phase 2 study of RP-A501 for Danon Disease.

Key Dates

Date	Description
March 2016	Entered into a license agreement with CIEMAT Group for PKD.
July 2016	Entered into a license agreement with CIEMAT Group and FIBHNJS for FA.
February 2017	Entered into a license agreement with UCSD for DD.
September 2017	Effective date of license agreement with CIEMAT Group and UCLB for LAD-I.
November 2017	Entered into a license agreement with CIEMAT Group and UCLB for LAD-I.
November 19, 2018	Entered into a license agreement with RGNX for DD.
April 30, 2019	CIRM awarded the Company up to $7.5 million under a CLIN2 grant award to support the clinical development of its LV-based gene therapy, RP-L201.
September 1, 2019	Start date of 15-year term for NJ Lease Agreement.
December 21, 2020	Warrant to Purchase Shares of Common Stock, dated as of December 21, 2020, by and between the Registrant and Neptune Consulting, LLC.
August 27, 2021	Registration Rights Agreement, dated as of August 27, 2021, by and among Rocket Pharmaceuticals, Inc., and each of those persons listed as an Investor on the Schedule of Inventors attached as Schedule A thereto
December 17, 2021	Warrant to Purchase Shares of Common Stock, dated as of December 17, 2021, by and between the Registrant and Neptune Consulting, LLC. (First Indication)
December 17, 2021	Warrant to Purchase Shares of Common Stock, dated as of December 17, 2021, by and between the Registrant and Neptune Consulting, LLC. (Second Indication)
February 28, 2022	Entered into a sales agreement with Cowen and Company, LLC for at-the-market offering program.
December 1, 2022	Completed acquisition of Renovacor.
January 16, 2023	Assignment, Assumption and Amended & Restated Warrant Agreement, dated January 16, 2023, by and among Rocket Pharmaceuticals, Inc., Zebrafish Merger Sub II, LLC, as successor to Renovacor, Inc., and Continental Stock Transfer & Trust Company
February 14, 2023	Severance and Change in Control Policy, effective as of February 14, 2023
September 12, 2023	Amendment No. 1 to the Sales Agreement, dated September 12, 2023, by and between the Company and Cowen and Company, LLC
September 15, 2023	Completed a public offering of approximately 9.5 million shares of its common stock at a public offering price of $16.00 per share and pre-funded warrants to purchase 3.1 million shares of common stock at a price of $15.99 per warrant.
March 25, 2024	Executive Employment Agreement, dated March 25, 2024, by and between the registrant and Aaron Ondrey
April 2, 2024	EMA accepted the MAA for RP-L102.
June 2024	FDA issued a Complete Response Letter for RP-L201.
August 18, 2024	CIRM awarded the Company up to $5.8 million under a CLIN2 grant award to support the clinical development of its AAV-based gene therapy, RP-A501 for the treatment of DD.
September 26, 2024	Submission of a BLA on a rolling review basis was initiated on September 26, 2024.
December 9, 2024	Entered into a Subscription Agreement with RTW Innovation Master Fund, Ltd.
December 12, 2024	Completed a public offering of approximately 15.2 million shares of its common stock at a public offering price of $12.50 per share and Private Placement of pre-funded warrants to purchase 0.4 million shares of common stock at a price of $12.49 per warrant.
February 21, 2025	As of February 21, 2025, there were 106,629,701 shares of common stock outstanding.
February 27, 2025	Date of filing of the 10K.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.